EBS — Emergent BioSolutions Share News
0.000.00%
Last trade - 00:00- $639.03m
- $1.08bn
- $742.90m
U.S. STOCKS ON THE MOVE-Veritex, Gaming and Leisure Properties, Apple
Emergent BioSolutions up after authorizing $50 million stock repurchase plan
Brief: Emergent Biosolutions finalizes sale of Baltimore-Bayview manufacturing site to Syngene International
Brief: Emergent Biosolutions And Rocketvax Announce Investment Agreement And Pursuit Of A Strategic Relationship For Next-Generation Product Candidates
India's Syngene International acquires first US biologics facility for $36.5 mln (updated)
Emergent BioSolutions drops after Syngene buys co's unit for $36.5 mln
India's Syngene International acquires first US biologics facility for $50 mln
U.S. STOCKS ON THE MOVE-Capricor, Wave Life Sciences, EVgo
U.S. STOCKS ON THE MOVE-Wellgistics, Capricor, Wave Life Sciences
Emergent BioSolutions falls on quarterly revenue decline
Emergent BioSolutions Inc reports results for the quarter ended December 31 - Earnings Summary
Emergent BioSolutions falls after reporting downbeat quarterly revenue
Brief: Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
U.S. STOCKS ON THE MOVE-Fortinet, KB Home, Goldman Sachs
U.S. STOCKS ON THE MOVE-Teladoc Health, Mustang Bio, Instacart
U.S. STOCKS ON THE MOVE-B Riley, H&E Equipment, Emergent BioSolutions
Emergent up on gaining commercial rights for Hikma's opioid overdose treatment
Brief: Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
Brief: Emergent Biosolutions Announces Exercise Of $20 Million Option To Supply U.S. Department Of Defense With Biothrax